Improved In-Vitro Fertilisation (IVF) implantation success rate using advanced proteomic analysis of embryo culture fluid.

在英国，七分之一的夫妇患有不孕症。子宫内膜异位症、多囊卵巢或排卵障碍影响了20%的女性，而男性不育症正在显著上升。世界卫生组织承认不孕症是一种疾病，它造成的破坏和悲伤是公认的。NHS为不孕夫妇提供有限的体外受精支持，但正在削减供应。私人诊所可以满足这一需求，但通常需要多次循环，成功率为25-30%，成本（每个周期1500 - 5000英镑）和压力都非常高。胚胎质量参差不齐，最好的胚胎最有可能植入并导致怀孕。胚胎学家利用训练和专业知识，根据物理标准和观察来选择胚胎，但这个过程既耗时又主观。胚胎镜和人工智能技术可能会改善结果，但每3-5天的疗程仅限于12个胚胎，并且只能提供视觉信息。市场对一种非侵入性、预测性、高通量、低成本的技术有着强烈的需求，这种技术可以提高植入成功率，减少周期次数。MAP科学公司开发了一个诊断平台，使用矩阵辅助激光解吸电离飞行时间质谱（MALDI-ToF）和先进的蛋白质模式识别，利用人工智能，从临床样本中诊断疾病状态。MAP的研究表明，快速分析胚胎培养基与选择具有最高着床潜力的胚胎有很强的相关性。MAP的突破性技术为最佳决策提供了高质量、客观的代谢数据，从根本上提高了植入成功率。该技术的主要特点是无侵入性或组织破坏性，快速，高通量和经济实惠。专利是在英国授予的。法国，德国，中国。Map需要资源来扩大数据集和范围，通过与试管婴儿诊所合作收集样本和数据，在技术和商业上验证技术，并创建具有IVDR - FDA验证的最终产品。MAP已获得仪器制造商的承诺，以确保MAP的软件/试剂技术与现有和新推出的机器一起快速引入和强大的支持。一个成功的项目结果在临床上、商业上、从患者的角度、情感上和经济上都很重要。

Infertility affects one in seven couples in the UK. Endometriosis, polycystic ovaries, or ovulation disorders affect 20% of women, while male infertility is rising significantly. The WHO recognises infertility as a disease, and the devastation and grief it causes is widely acknowledged.The NHS provides limited IVF support for infertile couples but is cutting provision. Private clinics service the need but with multiple cycles usually required and a 25-30% success rate, the costs (£1,500 - £5,000 per cycle) and stress involved are extremely high.Embryos vary in quality, the best most likely to implant and lead to a pregnancy. Embryologists use training and expertise to select embryos using physical criteria and observation but the process is time consuming and subjective. Embryoscope and AI technology potentially improves the outcome but is limited to 12 embryos per 3-5 day session and provides only visual information.There is a strong market need for a non-invasive, predictive technology, with high throughput and low cost, that can improve implantation success rate, and reduce the number of cycles.MAP Sciences has developed a diagnostic platform using Matrix Assisted Laser Desorption Ionisation Time of Flight Mass Spectrometry (MALDI-ToF) and advanced protein pattern recognition, using Artificial Intelligence, to diagnose disease states from clinical samples.MAP's research indicates strong correlation for rapid profiling of embryo culture media to select those embryos with highest implantation potential. MAP's ground-breaking technology provides high quality, objective metabolic data for optimal decision making, to radically improve implantation success rate. Key features of the technology are that is not invasive or tissue destructive, is rapid, high throughput, and affordable. Patents are granted in UK. France, Germany, China.Map requires resources to expand data sets and scope by collaborating with IVF clinics to collect samples and data to validate the technology both technically and commercially and create a final product with IVDR -- FDA validation.MAP has secured commitment from instrument manufacturers to ensure rapid introduction and robust support of MAP's software/reagent technology alongside existing and newly introduced machines.A successful project outcome is important clinically, commercially, and from the patient's perspective, emotionally and financially.